ONCOINVENT
Research ONCOINVENT (ONCIN.OL) on Bullrun: market cap NOK 420.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerONCIN.OL
- ExchangeXOSL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 420.08M
- Financial periodFY2025
- RevenueNOK 23.04M
- Revenue growth744.2%
- Net income-NOK 155.07M
- Free cash flow-NOK 129.99M
Valuation Snapshot
latest market cap is NOK 420.08M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 23.04M | -NOK 155.07M | -NOK 129.99M | n/a | -125 | NOK 173.46M | NOK 3.55M | NOK 146.33M |
| FY2024 | NOK 2.73M | -NOK 140.20M | -NOK 89.75M | n/a | -561 | NOK 131.35M | NOK 7.45M | NOK 108.33M |
| FY2023 | NOK 354.00K | -NOK 190.40M | -NOK 225.10M | n/a | -833.08 | NOK 155.97M | NOK 418.00K | NOK 127.48M |
| FY2022 | NOK 389.00K | -NOK 302.12M | -NOK 288.23M | n/a | -21852.43 | NOK 150.80M | NOK 275.00K | NOK 88.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-06 | NOK 420.08M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About ONCOINVENT
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ONCOINVENT's market cap?
ONCOINVENT's market capitalization is NOK 420.08M.
What does ONCOINVENT do?
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.